IL96841A - Preparations and method for the treatment of osteoporosis in mammals containing insulin-like growth factor I - Google Patents

Preparations and method for the treatment of osteoporosis in mammals containing insulin-like growth factor I

Info

Publication number: IL96841A
Authority: IL; Israel
Prior art keywords: igf; bone; mammal; composition; mineral density
Prior art date: 1990-01-03

Application number

IL9684190A

Other languages

English (en)

Hebrew (he)

Other versions

IL96841A0 (en

Original Assignee

Ciba Geigy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-01-03

Filing date

1990-12-31

Publication date

1996-05-14

1990-12-31 Application filed by Ciba Geigy filed Critical Ciba Geigy

1991-09-16 Publication of IL96841A0 publication Critical patent/IL96841A0/xx

1996-05-14 Publication of IL96841A publication Critical patent/IL96841A/en

Links

108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims abstract description 79
102000004218 Insulin-Like Growth Factor I Human genes 0.000 title claims abstract description 78
208000001132 Osteoporosis Diseases 0.000 title claims abstract description 38
241000124008 Mammalia Species 0.000 title claims abstract description 34
239000000203 mixture Substances 0.000 title claims abstract description 21
238000000034 method Methods 0.000 title abstract description 17
210000000988 bone and bone Anatomy 0.000 claims description 65
229910052500 inorganic mineral Inorganic materials 0.000 claims description 39
239000011707 mineral Substances 0.000 claims description 39
239000012634 fragment Substances 0.000 claims description 20
230000000123 anti-resoprtive effect Effects 0.000 claims description 16
230000009467 reduction Effects 0.000 claims description 16
241000894007 species Species 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 10
102000055006 Calcitonin Human genes 0.000 claims description 9
108060001064 Calcitonin Proteins 0.000 claims description 9
150000001875 compounds Chemical class 0.000 claims description 9
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 8
229960004015 calcitonin Drugs 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 8
230000037182 bone density Effects 0.000 claims description 7
230000001747 exhibiting effect Effects 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
238000001739 density measurement Methods 0.000 claims description 6
230000002829 reductive effect Effects 0.000 claims description 6
229940122361 Bisphosphonate Drugs 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
229940011871 estrogen Drugs 0.000 claims description 5
239000000262 estrogen Substances 0.000 claims description 5
230000001850 reproductive effect Effects 0.000 claims description 5
230000001568 sexual effect Effects 0.000 claims description 4
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 3
102000044162 human IGF1 Human genes 0.000 claims description 3
230000003449 preventive effect Effects 0.000 claims description 3
238000010188 recombinant method Methods 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
230000001225 therapeutic effect Effects 0.000 claims description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
101000741445 Homo sapiens Calcitonin Proteins 0.000 claims description 2
229940035811 conjugated estrogen Drugs 0.000 claims description 2
QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 claims description 2
229960005309 estradiol Drugs 0.000 claims description 2
229930182833 estradiol Natural products 0.000 claims description 2
229940045644 human calcitonin Drugs 0.000 claims description 2
-1 hydroxy-alkyl bisphosphonate Chemical class 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
206010017076 Fracture Diseases 0.000 description 8
241000700159 Rattus Species 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
208000010392 Bone Fractures Diseases 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
230000001054 cortical effect Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000008223 sterile water Substances 0.000 description 5
239000002671 adjuvant Substances 0.000 description 4
239000008121 dextrose Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 3
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000004067 bulking agent Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000000326 densiometry Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000009977 dual effect Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000000399 orthopedic effect Effects 0.000 description 3
230000011164 ossification Effects 0.000 description 3
210000000689 upper leg Anatomy 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
208000006386 Bone Resorption Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
230000032683 aging Effects 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000024279 bone resorption Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
229960002591 hydroxyproline Drugs 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000009806 oophorectomy Methods 0.000 description 2
210000000963 osteoblast Anatomy 0.000 description 2
230000001009 osteoporotic effect Effects 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
206010041569 spinal fracture Diseases 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
101000741443 Bos taurus Calcitonin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
KSIYPKPZIBBUFR-LJNLPFSOSA-N CSCC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O Chemical compound CSCC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O KSIYPKPZIBBUFR-LJNLPFSOSA-N 0.000 description 1
102100038518 Calcitonin Human genes 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
206010010214 Compression fracture Diseases 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
101000741447 Gallus gallus Calcitonin Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101150088952 IGF1 gene Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108010048233 Procalcitonin Proteins 0.000 description 1
101000910301 Rattus norvegicus Calcitonin Proteins 0.000 description 1
206010039984 Senile osteoporosis Diseases 0.000 description 1
102000013275 Somatomedins Human genes 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000012491 analyte Substances 0.000 description 1
230000003262 anti-osteoporosis Effects 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
210000002449 bone cell Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
URGZBUPIVSHGEI-UHFFFAOYSA-N calcitonin rat Chemical compound C1CCC(C(N)=O)N1C(=O)C(C)NC(=O)CNC(=O)C(C(C)C)NC(=O)CNC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(NC(=O)C(NC(=O)C(CC=1NC=NC=1)NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(CCCCN)NC(=O)C(CC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CC=1C=CC(O)=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CCSC)NC(=O)C1NC(=O)C(C(C)O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)CNC(=O)C(N)CSSC1)C(C)O)C(C)O)C(C)O)CC1=CC=CC=C1 URGZBUPIVSHGEI-UHFFFAOYSA-N 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000002745 epiphysis Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000000413 hydrolysate Substances 0.000 description 1
201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000002601 radiography Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
108010068072 salmon calcitonin Proteins 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000003325 tomography Methods 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
JDJALSWDQPEHEJ-LMVCGNDWSA-N x4853 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 JDJALSWDQPEHEJ-LMVCGNDWSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Obesity (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

IL9684190A 1990-01-03 1990-12-31 Preparations and method for the treatment of osteoporosis in mammals containing insulin-like growth factor I IL96841A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US46041690A	1990-01-03	1990-01-03

Publications (2)

Publication Number	Publication Date
IL96841A0 IL96841A0 (en)	1991-09-16
IL96841A true IL96841A (en)	1996-05-14

Family

ID=23828617

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9684190A IL96841A (en)	1990-01-03	1990-12-31	Preparations and method for the treatment of osteoporosis in mammals containing insulin-like growth factor I

Country Status (15)

Country	Link
US (2)	US5646116A (es)
EP (1)	EP0436469B1 (es)
JP (1)	JP3053116B2 (es)
KR (1)	KR100200995B1 (es)
AT (1)	ATE118172T1 (es)
AU (1)	AU629443B2 (es)
CA (1)	CA2033469C (es)
DE (1)	DE69016768T2 (es)
DK (1)	DK0436469T3 (es)
ES (1)	ES2067720T3 (es)
GR (1)	GR3015490T3 (es)
IE (1)	IE66240B1 (es)
IL (1)	IL96841A (es)
NZ (1)	NZ236618A (es)
ZA (1)	ZA916B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69133087T2 (de) *	1990-05-30	2003-04-03	Institute Of Molecular Biology Inc., Boston	Kombination aus IGF-I und TGF-beta zur Knochenregenerierung
US7056882B2 (en)	1991-03-11	2006-06-06	Curis, Inc.	Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5674844A (en) *	1991-03-11	1997-10-07	Creative Biomolecules, Inc.	Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5118667A (en) *	1991-05-03	1992-06-02	Celtrix Pharmaceuticals, Inc.	Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5202119A (en) *	1991-06-28	1993-04-13	Genentech, Inc.	Method of stimulating immune response
TW267102B (es) *	1992-03-13	1996-01-01	Ciba Geigy
JPH08500123A (ja) *	1993-01-25	1996-01-09	ザベスイスラエルホスピタルアソシエイション	Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法
WO1996002565A1 (en) *	1994-07-20	1996-02-01	Celtrix Pharmaceuticals, Inc.	Igf/igfbp complex for promoting bone formation and for regulating bone remodeling
US5712249A (en) *	1994-09-08	1998-01-27	Ciba-Geigy Corporation	Use of insulin-like growth factors I and II for inhibition of inflammatory response
WO1996007744A1 (en) *	1994-09-08	1996-03-14	Chiron Corporation	A method of improved production of insulin-like growth factor
US5622932A (en) *	1995-05-05	1997-04-22	Eli Lilly And Company	IGF-1 superagonists
US7026292B1 (en)	1995-12-12	2006-04-11	Stryker Corporation	Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6048964A (en) *	1995-12-12	2000-04-11	Stryker Corporation	Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
JP2000512274A (ja) *	1996-05-31	2000-09-19	ノボノルディスクアクティ―ゼルスカブ	骨粗しょう症の周期的（整合性）治療における成長ホルモン成分及び骨抗吸収剤
US6025368A (en) *	1997-02-25	2000-02-15	Celtrix Pharmaceuticals, Inc.	Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en)	1997-02-25	2003-02-04	Celtrix Pharmaceuticals, Inc.	Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) *	1997-02-25	2000-01-18	Celtrix Pharmaceuticals, Inc.	Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6627746B1 (en)	1998-04-17	2003-09-30	Exelixis, Inc.	Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
AU762351B2 (en)	1999-01-06	2003-06-26	Genentech Inc.	Insulin-like growth factor (IGF) I mutant variants
US6846496B1 (en) *	1999-10-15	2005-01-25	Orion Corporation	Treatment of osteoporosis
AU4935701A (en)	2000-03-24	2001-10-08	Genentech Inc	Use of insulin for the treatment of cartilagenous disorders
AU2001263215A1 (en)	2000-05-16	2001-11-26	Genentech Inc.	Method for treating cartilage disorders
CA2372450A1 (en) *	2001-05-10	2001-09-19	Pharmaceutical Partners Of Canada Inc.	Liquid injectable formulation of disodium pamidronate
US7189233B2 (en) *	2001-10-22	2007-03-13	Surgrx, Inc.	Electrosurgical instrument
US7812120B2 (en)	2003-03-21	2010-10-12	Par Pharmaceutical, Inc.	Nasal calcitonin formulations containing chlorobutanol
JPWO2005002590A1 (ja) *	2003-07-01	2006-08-10	アステラス製薬株式会社	骨量増加誘導剤
US20050171015A1 (en) *	2003-10-31	2005-08-04	Crabtree Gerald R.	Methods and agents for enhancing bone formation or preventing bone loss
US7901710B2 (en)	2005-08-04	2011-03-08	Vertical Pharmaceuticals, Inc.	Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en)	2005-08-04	2011-08-16	Vertical Pharmaceuticals, Inc.	Nutritional supplement for women
US8202546B2 (en)	2005-08-04	2012-06-19	Vertical Pharmaceuticals, Inc.	Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en)	2005-08-04	2012-09-11	Vertical Pharmaceuticals, Inc.	Nutritional supplement for women
US20080200425A1 (en) *	2007-02-16	2008-08-21	Kurtz Seymour J	Methods and compositions for regulating bone mineral density
WO2014143992A1 (en) *	2013-03-15	2014-09-18	University Of Rochester	Treating lysosomal storage disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE95236T1 (de) *	1983-04-25	1993-10-15	Chiron Corp	Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren.
US4774091A (en) *	1983-10-14	1988-09-27	Sumitomo Pharmaceuticals Company, Ltd.	Long-term sustained-release preparation
ATE112684T1 (de) *	1987-04-28	1994-10-15	Boehringer Mannheim Gmbh	Verwendung von igf-ii zur behandlung von knochenkrankheiten.
US4876242A (en) *	1987-09-21	1989-10-24	Merck & Co., Inc.	Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
IL88344A (en) *	1987-11-12	1994-06-24	Schering Corp	Accelerating bone formation using a factor that accelerates colonies of granulocyte macrophages

1990
- 1990-12-21 NZ NZ236618A patent/NZ236618A/en unknown
- 1990-12-27 DE DE69016768T patent/DE69016768T2/de not_active Expired - Fee Related
- 1990-12-27 ES ES90811032T patent/ES2067720T3/es not_active Expired - Lifetime
- 1990-12-27 AU AU68532/90A patent/AU629443B2/en not_active Ceased
- 1990-12-27 AT AT90811032T patent/ATE118172T1/de not_active IP Right Cessation
- 1990-12-27 DK DK90811032.3T patent/DK0436469T3/da active
- 1990-12-27 EP EP90811032A patent/EP0436469B1/en not_active Expired - Lifetime
- 1990-12-28 JP JP2418819A patent/JP3053116B2/ja not_active Expired - Fee Related
- 1990-12-31 IL IL9684190A patent/IL96841A/en not_active IP Right Cessation
- 1990-12-31 KR KR1019900022587A patent/KR100200995B1/ko not_active Expired - Fee Related
- 1990-12-31 CA CA002033469A patent/CA2033469C/en not_active Expired - Fee Related
1991
- 1991-01-02 IE IE491A patent/IE66240B1/en not_active IP Right Cessation
- 1991-01-02 ZA ZA916A patent/ZA916B/xx unknown
1995
- 1995-03-01 US US08/396,884 patent/US5646116A/en not_active Expired - Fee Related
- 1995-03-20 GR GR950400621T patent/GR3015490T3/el unknown
1996
- 1996-12-30 US US08/774,510 patent/US6174857B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IE910004A1 (en)	1991-07-17
AU629443B2 (en)	1992-10-01
GR3015490T3 (en)	1995-06-30
IE66240B1 (en)	1995-12-13
US5646116A (en)	1997-07-08
CA2033469C (en)	2003-01-28
ZA916B (en)	1991-08-28
KR100200995B1 (ko)	1999-06-15
IL96841A0 (en)	1991-09-16
KR910021243A (ko)	1991-12-20
US6174857B1 (en)	2001-01-16
CA2033469A1 (en)	1991-07-04
JPH04235135A (ja)	1992-08-24
EP0436469B1 (en)	1995-02-08
DE69016768T2 (de)	1995-06-14
JP3053116B2 (ja)	2000-06-19
ES2067720T3 (es)	1995-04-01
AU6853290A (en)	1991-07-04
EP0436469A1 (en)	1991-07-10
ATE118172T1 (de)	1995-02-15
NZ236618A (en)	1997-06-24
DK0436469T3 (da)	1995-04-03
DE69016768D1 (de)	1995-03-23

Legal Events

Date	Code	Title
1996-10-16	FF	Patent granted
1996-12-05	KB	Patent renewed
1998-02-08	HC	Change of name of proprietor(s)
2001-04-30	KB	Patent renewed
2005-02-20	KB	Patent renewed
2010-04-08	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
CA2033469C (en)	2003-01-28	Composition and method for the treatment of osteoporosis in mammals
KR100306852B1 (ko)	2001-11-30	골량을 증가시키기위한 부갑상선호르몬 및 랄옥시펜
JP2831132B2 (ja)	1998-12-02	骨の形成を促進するための骨成長因子および骨吸収阻害剤
Overgaard et al.	1989	Effect of salcatonin given intranasally on early postmenopausal bone loss.
EP0571417B1 (en)	1996-03-20	Combination of igf-i and igfbp for anabolism
KR100454207B1 (ko)	2004-10-26	뼈 인성 및 강성의 증가와 골절의 감소 방법
AU645874B2 (en)	1994-01-27	Treatment for osteoporosis using growth hormone release factor (GRF) in combination with parathyroid hormone (PTH)
Rosen et al.	1995	Treatment with growth hormone and IGF‐I in growing rats increases bone mineral content but not bone mineral density
AU666514B2 (en)	1996-02-15	Method and composition for the treatment of osteoporosis
JP2009508820A (ja)	2009-03-05	副甲状腺ホルモンアナログおよび使用法
EP0289314A2 (en)	1988-11-02	Use of IGF-II in the treatment of bone disorders
JPH04500691A (ja)	1992-02-06	骨疾患の治療
JPH0873376A (ja)	1996-03-19	骨粗鬆症治療薬
EP1755637B1 (en)	2012-08-29	Methods for preventing or treating bone disorders
EP1799240A2 (en)	2007-06-27	Treatment of bone disorders with skeletal anabolic drugs
JP2008540522A (ja)	2008-11-20	骨の形成および保存を促進するための方法
US20030027753A1 (en)	2003-02-06	Bone stimulating factor